Organ-Specific Tumor Response to Pembrolizumab in Advanced Urothelial Carcinoma After Platinum-Based Chemotherapy

References

• Maase HVD, Sengelov L, Roberts JT, et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol. 2005;23(21):4602–4608. doi:10.1200/JCO.2005.07.757
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. Guidelines on bladder cancer. July 16, 2020. Available from: https://www.nccn.org/professionals/physician_gls/pdf/bladder.pdf. Accessed November 1, 2020.
   Google Scholar
• Sternberg CN, Yagoda A, Scher HI, et al. M-VAC: methotrexate (MTX), vinblastine (VLB), adriamycin (ADM), and cisplatin (DDP) for metastatic and node positive carcinoma of the urothelium. Prog Clin Biol Res. 1988;260:481–485.
   PubMedGoogle Scholar
• Plimack ER, Bellmunt J, Gupta S, et al. Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study. Lancet Oncol. 2017;18(2):212–220. doi:10.1016/S1470-2045(17)30007-4
   PubMed Web of Science ®Google Scholar
• Santis MD, Bellmunt J, Mead G, et al. Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. J Clin Oncol. 2012;30(2):191–199. doi:10.1200/JCO.2011.37.3571
   PubMed Web of Science ®Google Scholar
• Sweeney CJ, Roth BJ, Kabbinavar FF, et al. Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium. J Clin Oncol. 2006;24(21):3451–3457. doi:10.1200/JCO.2005.03.6699
   PubMed Web of Science ®Google Scholar
• Seidel JA, Otsuka A, Kabashima K. Anti-PD-1 and anti-CTLA-4 therapies in cancer: mechanisms of action, efficacy, and limitations. Front Oncol. 2018;8:86. doi:10.3389/fonc.2018.00086
   PubMed Web of Science ®Google Scholar
• Califano G, Ouzaid I, Verze P, et al. Immune checkpoint inhibition in upper tract urothelial carcinoma. World J Urol. 2020. doi:10.1007/s00345-020-03502-7
   PubMedGoogle Scholar
• Califano G, Ouzaid I, Verze P, et al. New immunotherapy treatments in non-muscle invasive bladder cancer. Arch Esp Urol. 2020;73(10):945–953.
   PubMed Web of Science ®Google Scholar
• Yuasa T, Urakami S, Yonese J. Recent advances in medical therapy for metastatic urothelial cancer. Int J Clin Oncol. 2018;23(4):599–607. doi:10.1007/s10147-018-1260-0
   PubMed Web of Science ®Google Scholar
• Bellmunt J, Wit RD, Vaughn DJ, et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med. 2017;376(11):1015–1026. doi:10.1056/NEJMoa1613683
   PubMed Web of Science ®Google Scholar
• Schmid S, Diem S, Li O, et al. Organ-specific response to nivolumab in patients with non-small cell lung cancer (NSCLC). Cancer Immunol Immunother. 2018;67(12):1825–1832. doi:10.1007/s00262-018-2239-4
   PubMed Web of Science ®Google Scholar
• Lu LC, Hsu C, Shao YY, et al. Differential organ-specific tumor response to immune checkpoint inhibitors in hepatocellular carcinoma. Liver Cancer. 2019;8(6):480–490. doi:10.1159/000501275
   PubMed Web of Science ®Google Scholar
• Silva PDI, Lo S, Quek C, et al. Site-specific response patterns, pseudoprogression, and acquired resistance in patients with melanoma treated with ipilimumab combined with anti-PD-1 therapy. Cancer. 2020;126(1):86–97. doi:10.1002/cncr.32522
   PubMed Web of Science ®Google Scholar
• Moch H, Cubilla AL, Humphrey PA, et al. The 2016 WHO classification of tumours of the urinary system and male genital organs-part A: renal, penile, and testicular tumours. Eur Urol. 2016;70(1):93–105. doi:10.1016/j.eururo.2016.02.029
   PubMed Web of Science ®Google Scholar
• Furubayashi N, Negishi T, Miura A, et al. Organ-specific therapeutic effect of paclitaxel and carboplatin chemotherapy after platinum-based chemotherapy and pembrolizumab for metastatic urothelial carcinoma. Res Rep Urol. 2020;12:455–461. doi:10.2147/RRU.S270495
   PubMed Web of Science ®Google Scholar
• Kessel CSV, Samim M, Koopman M, et al. Radiological heterogeneity in response to chemotherapy is associated with poor survival in patients with colorectal liver metastases. Eur J Cancer. 2013;49(11):2486–2493. doi:10.1016/j.ejca.2013.03.027
   PubMed Web of Science ®Google Scholar
• Chen ZY, Zhong WZ, Zhang XC, et al. EGFR mutation heterogeneity and the mixed response to EGFR tyrosine kinase inhibitors of lung adenocarcinomas. Oncologist. 2012;17(7):978–985. doi:10.1634/theoncologist.2011-0385
   PubMed Web of Science ®Google Scholar
• Mete UK, Singh DV, Kakkar N, et al. Sustained systemic response paralleled with ovarian metastasis progression by sunitinib in metastatic renal cell carcinoma: is this an anti-angiogenic potentiation of cancer? Urol Ann. 2015;7(3):387–390. doi:10.4103/0974-7796.153669
   PubMedGoogle Scholar
• Goasguen N, Chaisemartin CD, Brouquet A, et al. Evidence of heterogeneity within colorectal liver metastases for allelic losses, mRNA level expression and in vitro response to chemotherapeutic agents. Int J Cancer. 2010;127(5):1028–1037. doi:10.1002/ijc.25114
   PubMed Web of Science ®Google Scholar
• Schmid K, Oehl N, Wrba F, et al. EGFR/KRAS/BRAF mutations in primary lung adenocarcinomas and corresponding locoregional lymph node metastases. Clin Cancer Res. 2009;15(14):4554–4560. doi:10.1158/1078-0432.CCR-09-0089
   PubMed Web of Science ®Google Scholar
• Krantz D, Hartana CA, Winerdal ME, et al. Neoadjuvant chemotherapy reinforces antitumour T cell response in urothelial urinary bladder cancer. Eur Urol. 2018;74(6):688–692. doi:10.1016/j.eururo.2018.06.048
   PubMed Web of Science ®Google Scholar
• Zirakzadeh AA, Kinn J, Krantz D, et al. Doxorubicin enhances the capacity of B cells to activate T cells in urothelial urinary bladder cancer. Clin Immunol. 2017;176:63–70. doi:10.1016/j.clim.2016.12.003
   PubMed Web of Science ®Google Scholar
• Hu J, Kinn J, Zirakzadeh AA, et al. The effects of chemotherapeutic drugs on human monocyte-derived dendritic cell differentiation and antigen presentation. Clin Exp Immunol. 2013;172(3):490–499. doi:10.1111/cei.12060
   PubMed Web of Science ®Google Scholar
• Grisay G, Pierrard J, Confente C, et al. Future strategies involving immune checkpoint inhibitors in advanced urothelial carcinoma. Curr Treat Options Oncol. 2020;22(1):7. doi:10.1007/s11864-020-00799-9
   PubMed Web of Science ®Google Scholar
• Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92(3):205–216. doi:10.1093/jnci/92.3.205
   PubMed Web of Science ®Google Scholar
• Grunwald V, Choueiri TK, Rini BI, et al. Association between depth of response and overall survival: exploratory analysis in patients with previously untreated advanced renal cell carcinoma (aRCC) in CheckMate 214. Ann Oncol. 2019;30(suppl 5):v356–402 (abstr). doi:10.1093/annonc/mdz249.046
   Google Scholar
• Osgood C, Mulkey F, Mishra-Kalyani PS, et al. FDA analysis of depth of response (DpR) and survival across 10 randomized controlled trials in patients with previously untreated unresectable or metastatic melanoma (UMM) by therapy type. Proc Am Soc Clin Oncol. 2019;37(suppl 15):9508 (abstr 9508).
   Google Scholar
• Bellmunt J, Choueiri TK, Fougeray R, et al. Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens. Clin Oncol. 2010;28(11):1850–1855. doi:10.1200/JCO.2009.25.4599
   Web of Science ®Google Scholar
• Sonpavde G, Pond GR, Fougeray R, et al. Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: a retrospective analysis of pooled, prospective Phase 2 trials. Eur Urol. 2013;63(4):717–723. doi:10.1016/j.eururo.2012.11.042
   PubMed Web of Science ®Google Scholar
• Chan T, Wiltrout RH, Weiss JM. Immunotherapeutic modulation of the suppressive liver and tumor microenvironments. Int Immunopharmacol. 2011;11(7):879–889. doi:10.1016/j.intimp.2010.12.024
   PubMed Web of Science ®Google Scholar
• Tiegs G, Lohse AW. Immune tolerance: what is unique about the liver. J Autoimmun. 2010;34(1):1–6. doi:10.1016/j.jaut.2009.08.008
   PubMed Web of Science ®Google Scholar